Aristides Capital LLC Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Aristides Capital LLC bought a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,000 shares of the company’s stock, valued at approximately $325,000. Aristides Capital LLC owned about 0.08% of Delcath Systems as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in Delcath Systems by 14.7% in the fourth quarter. Geode Capital Management LLC now owns 288,951 shares of the company’s stock valued at $3,481,000 after buying an additional 37,056 shares during the last quarter. Principal Financial Group Inc. raised its position in Delcath Systems by 28.8% in the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock valued at $1,387,000 after purchasing an additional 25,736 shares during the last quarter. Diametric Capital LP boosted its stake in Delcath Systems by 39.6% during the 4th quarter. Diametric Capital LP now owns 94,737 shares of the company’s stock worth $1,141,000 after purchasing an additional 26,881 shares during the period. State Street Corp grew its position in Delcath Systems by 12.4% during the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after purchasing an additional 9,400 shares during the last quarter. Finally, ExodusPoint Capital Management LP increased its stake in Delcath Systems by 32.2% in the fourth quarter. ExodusPoint Capital Management LP now owns 51,697 shares of the company’s stock valued at $622,000 after purchasing an additional 12,604 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Stock Down 8.3 %

NASDAQ DCTH opened at $11.01 on Monday. Delcath Systems, Inc. has a 52-week low of $4.26 and a 52-week high of $16.97. The firm has a 50-day moving average price of $14.28 and a 200 day moving average price of $12.14. The stock has a market capitalization of $367.77 million, a P/E ratio of -8.16 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same period in the prior year, the business earned ($0.48) earnings per share. On average, equities research analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DCTH has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Craig Hallum lifted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.